Multiple myeloma and chronic leukaemias in 2014: Improved understanding of disease biology and treatment
San Miguel JF (1), Kantarjian HM (2).
(1) Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Avenida Pio XII 55, 31008 Pamplona, Spain.
(2) MD Anderson Cancer Center, University of Texas, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA.
In 2014, strides were made in the care of haematological malignancies. In particular, the heterogeneity of multiple myeloma was unravelled, and new diagnostic criteria and frontline standards of care were proposed; new therapeutic approaches have been validated and approved in chronic lymphocytic leukaemia; and in chronic myeloid leukaemia, complete cytogenetic response was confirmed as the primary therapeutic end point.
CITA DEL ARTÍCULO Nat Rev Clin Oncol. 2014 Dec 16. doi: 10.1038/nrclinonc.2014.216.